IP Library Granted Patent US 10,064,674
Granted Patent B2
US 10,064,674 · App. 14/832,302 · Granted Sep 4, 2018

Methods of modulating nerves of the hepatic plexus

Inventors: Bobak Robert Azamian (Newport Coast, CA); Scott Bradley Vafai (Boston, MA)
Assignee: Metavention, Inc.
A61B18/02A61B17/00A61B17/00234A61B17/32A61B17/320068A61B18/04A61B18/06A61B18/1492A61B18/18A61B18/1815A61B18/20A61B18/24A61K9/0019A61K31/045A61K31/05A61K31/395A61K33/30A61K45/06A61M5/14A61N1/0551A61N5/00A61N7/00A61B2017/00318A61B2018/0022A61B2018/00023A61B2018/00214A61B2018/00404A61B2018/00434A61B2018/00529A61B2018/00577A61B2018/00732A61B2018/00791A61B2018/00839A61B2018/00994A61B2018/0212A61B2018/048A61B2018/1861A61N7/022
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,064,674
App. No.
14/832,302
Granted
Sep 4, 2018
Kind
B2
Abstract

According to some embodiments, a method of treating a subject having diabetes or symptoms associated with diabetes is provided. The method includes delivering a neuromodulation catheter within a vessel (e.g., hepatic artery) having surrounding nerves that innervate the liver (e.g., sympathetic nerves of the hepatic plexus). The method may also include modulating (e.g., disrupting, ablating, stimulating) the nerves by mechanical compression, energy delivery, or fluid delivery.

Claims (39)

1. A method of facilitating hepatic neuromodulation, the method comprising:

inserting a catheter within a common hepatic artery of a subject;

delivering a chemical agent through the catheter to nerves within or surrounding a wall of the common hepatic artery,

wherein the nerves comprise sympathetic nerves of a hepatic plexus;

wherein the chemical agent is configured to ablate the nerves in a manner that facilitates a reduction in at least one of a blood glucose level or a lipoprotein level of the subject; and

removing the catheter from the subject.

2. The method of claim 1 , wherein the chemical agent is a chemoablation agent.

3. The method of claim 2 , wherein the chemoablation agent comprises an alcohol.

4. The method of claim 1 , wherein the chemical agent is configured to affect at least one of neurotransmission synthesis, degradation or reuptake.

5. The method of claim 1 , wherein the chemical agent is selected from the group consisting of: a phenol, a neurotoxin, guanethidine, zinc sulfate, nanoparticles, neurostimulants, and oxygen radicals.

6. The method of claim 1 ,

wherein the chemical agent is a chemoablation agent.

7. The method of claim 1 , further comprising delivering the chemical agent through the catheter to nerves of a celiac plexus.

8. A method of facilitating hepatic neuromodulation, the method comprising:

inserting a delivery catheter within a subject;

positioning the delivery catheter at a location proximate nerves that innervate a liver of the subject; and

modulating the nerves by delivering a drug through the delivery catheter to the nerves,

wherein the drug is configured to modulate the nerves in a manner that facilitates a reduction in at least one of a blood glucose level or a lipoprotein level of the subject, and

wherein the nerves comprise nerves of a hepatic plexus.

9. The method of claim 8 , wherein the drug comprises a chemoablation agent, and wherein said modulating comprises ablating the nerves.

10. The method of claim 8 , wherein the drug comprises an alcohol, wherein said alcohol modulates said nerves by deactivating said nerves.

11. The method of claim 8 , wherein the drug is configured to have an inhibitory effect on the nerves.

12. The method of claim 8 , further comprising confirming said modulating of the nerves.

13. The method of claim 8 ,

wherein inserting the delivery catheter within the subject comprises inserting the delivery catheter within vasculature of the subject,

wherein positioning the delivery catheter at the location proximate nerves that innervate the liver of the subject comprises positioning a distal end of the delivery catheter at a location within a hepatic artery of the subject;

wherein the nerves comprise sympathetic nerves of a hepatic plexus,

wherein the drug is a chemoablation agent, and

wherein said modulating comprises ablating the nerves.

14. The method of claim 8 , wherein the nerves comprise sympathetic nerves of the hepatic plexus.

15. A method of facilitating hepatic neuromodulation, the method comprising:

delivering a fluid to nerves of a hepatic plexus of a subject,

wherein the fluid comprises an ablative fluid, and

wherein the ablative fluid causes deactivation of the nerves sufficient to facilitate a reduction in sympathetic activity of the subject.

16. The method of claim 15 , wherein the ablative fluid comprises alcohol.

17. The method of claim 15 , wherein the ablative fluid comprises a chemical agent selected from the group consisting of: a phenol, a neurotoxin, guanethidine, zinc sulfate, nanoparticles, neurostimulants, and oxygen radicals.

18. The method of claim 15 , wherein said delivering comprises delivering the fluid through a fluid delivery catheter or needle via one of a percutaneous, laparoscopic or intravascular approach.

19. The method of claim 15 , wherein the nerves comprise sympathetic nerves within or surrounding at least one of a hepatic artery or a gastroduodenal artery.

20. The method of claim 19 , further comprising positioning a delivery catheter or needle within at least one of the hepatic artery or the gastroduodenal artery, wherein the sympathetic nerves are within an adventitial layer of the hepatic artery or the gastroduodenal artery, wherein said delivering of the fluid to the nerves comprises delivering an alcohol to the adventitial layer in a localized manner, thereby leaving surrounding tissue unaffected, and wherein the deactivation of said nerves reduces at least one of a glucose level, a triglyceride level, and a lipoprotein level.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2023
From: METAVENTION, INC.
To: MEDTRONIC IRELAND MANUFACTURING UNLIMITED COMPANY
Reel/Frame 064987/0161 →
RELEASE OF SECURITY INTEREST Recorded Aug 22, 2023
From: CUSTOMERS BANK (SUCCESSOR IN INTEREST TO SIGNATURE BANK)
To: METAVENTION, INC.
Reel/Frame 064670/0039 →
SECURITY INTEREST Recorded Jan 11, 2023
From: METAVENTION, INC.
To: RVLHC II, LLC, AS COLLATERAL AGENT
Reel/Frame 062349/0859 →
SECURITY INTEREST Recorded Oct 31, 2022
From: METAVENTION, INC.
To: RVLHC II, LLC, AS COLLATERAL AGENT
Reel/Frame 061602/0249 →
SECURITY INTEREST Recorded Jun 29, 2022
From: METAVENTION, INC.
To: RVLHC II, LLC, AS COLLATERAL AGENT
Reel/Frame 060358/0417 →
SECURITY INTEREST Recorded Dec 20, 2021
From: METAVENTION, INC.
To: SIGNATURE BANK
Reel/Frame 058433/0587 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2017
From: AZAMIAN, BOBAK ROBERT; VAFAI, SCOTT BRADLEY
To: METAVENTION, INC.
Reel/Frame 041986/0248 →
Continuity (7)
Continuation 14530408 · Oct 31, 2014
Continuation 14279740 · May 16, 2014
Continuation 14061638 · Oct 23, 2013
Continuation 13789521 · Mar 7, 2013
Continuation PCTUS2012068630 · Dec 7, 2012
Provisional Application 61568843 · Dec 9, 2011
Related Publication 20160051465A1 · Feb 25, 2016
Cited By (3)
US 12,408,974 US 12,478,806 US 12,539,167